Faculty profile

Auro Viswabandya

Back to faculty

Associate ProfessorDepartment of MedicineUniversity of Toronto

Auro Viswabandya

Associate Professor

Department of Medicine

Temerty Faculty of Medicine

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
60 publications in the last five years, latest in 2026.
Senior (last) author on 13 recent papers, a sign of leading a research group.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

779

Citations

Collaborators

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile

Search on Google Scholar

Search on ResearchGate

iDORCID OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Toronto profile.

Latest papers

Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia.
British journal of haematology · 2026 · senior author
Impact of Graft-Versus-Host Disease Prophylaxis on Long-Term Outcomes in Patients Surviving Beyond Two Years After Allogeneic Transplantation.
JCO oncology practice · 2026
Frailty as a Prognostic Factor in Younger Adult Patients With Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
Transplantation and cellular therapy · 2026

All 97 publications

97 publications.

Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia.

Desai N, Althobaiti M, Chen C, Al-Shaibani E, Moya TA, Novitzky-Basso I, Pasic I, Michelis FV, Kim DD, Kumar R, Mattsson J, Law AD, Viswabandya A

British journal of haematology20263 citationsSenior author

DOI: 10.1111/bjh.70380 PMID: 41747740

Impact of Graft-Versus-Host Disease Prophylaxis on Long-Term Outcomes in Patients Surviving Beyond Two Years After Allogeneic Transplantation.

Desai N, Rodriguez-Rodriguez S, Chen C, Al-Shaibani E, Alfaro Moya T, Novitzky-Basso I, Pasic I, Michelis FV, Viswabandya A, Kim DDH, Kumar R, Mattsson J, Law AD

JCO oncology practice20261 citations

DOI: 10.1200/op-25-01308 PMID: 42372210

Frailty as a Prognostic Factor in Younger Adult Patients With Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.

Rodriguez-Rodriguez S, Salas MQ, Desai N, Al-Shaibani E, Novitzky-Basso I, Pasic I, Viswabandya A, Michelis FV, Mattsson J, Kim DDH, Kumar R, Moya TA

Transplantation and cellular therapy20261 citations

DOI: 10.1016/j.jtct.2026.01.026 PMID: 41571188

Herpes Zoster Frequency and Adjuvanted Recombinant Zoster Vaccination after Allogeneic Hematopoietic Cell Transplantation.

Hall VG, Chiarello C, Remberger M, Kumar D, Pasic I, Kim DDH, Kumar R, Viswabandya A, Michelis FV, Law A, Gerbitz A, Humar S, Lam W, Novitzky-Basso I, Mattsson J

Transplantation and cellular therapy20261 citations

DOI: 10.1016/j.jtct.2025.10.028 PMID: 41167523

CMV reactivation post allogeneic stem cell transplantation decreases relapse risk and survival, and increases NRM - a single center analysis.

Stavi V, Chen C, Novitzky-Basso I, Remberger M, Law A, Gerbitz A, Viswabandya A, Kim DDH, Michelis FV, Pasic I, Kumar R, Lam W, Mattsson J, Lipton JH

Leukemia & lymphoma2026

DOI: 10.1080/10428194.2026.2668034 PMID: 42132052

Size Does Not Always Matter: Limited Impact of Donor-recipient Weight Difference on Outcomes of Adult Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplantation.

Chiarello C, Singhabahu S, Remberger M, Chen C, Moya TA, Al-Shaibani E, Gerbitz A, Kim DDH, Kumar R, Lam W, Law AD, Lipton JH, Michelis FV, Novitzky-Basso I, Viswabandya A, Mattsson J, Pasic I

Transplantation and cellular therapy2026

DOI: 10.1016/j.jtct.2025.10.002 PMID: 41062023

Prior Malignancy History and Risk of Second Malignancies After Allogeneic Hematopoietic Cell Transplantation.

Desai N, Al-Shaibani E, Alfaro-Moya T, Law AD, Lam W, Pasic I, Novitzky-Basso I, Viswabandya A, Kim DD, Kumar R, Lipton JH, Mattsson J, Michelis FV

Transplantation and cellular therapy2026

DOI: 10.1016/j.jtct.2026.05.018 PMID: 42142626

Ferritin as a Pre-Transplant Biomarker for Post-Transplant Outcomes in Allogeneic Stem Cell Transplantation Using Post-Transplant Cyclophosphamide.

Rodriguez-Rodriguez S, Chiarello C, Desai N, Remberger M, Chen C, Al-Shaibani E, Alfaro Moya T, Law AD, Pasic I, Viswabandya A, Michelis FV, Kim DDH, Kumar R, Mattsson J, Novitzky-Basso I

Transplantation and cellular therapy2026

DOI: 10.1016/j.jtct.2026.03.015 PMID: 41839367

Changes in unrelated donor usage for allogeneic hematopoietic cell transplant in Canada: 2013–2023 and identifying priorities in donor selection

Hasan T, Seftel M, Wright P, Guo Y, Chartrand E, Green M, Jamani K, Viswabandya A, Popradi G, Lepic K

Transfusion2026

DOI: 10.1111/trf.70285

Regulatory Ambiguity in Hematopoietic Cell Transplantation in India: A National Survey.

John MJ, Malhotra P, Damodar S, Nair LGV, Majhail NS, Viswabandya A, Mahmud N, Sidharthan N, Philip CC, Abraham J, Kakkar S, Trivedi C, Aggarwal H

Transplantation and cellular therapy2026

DOI: 10.1016/j.jtct.2026.04.040 PMID: 42119784

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Auro Viswabandya

Research

Latest papers

Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia.

Impact of Graft-Versus-Host Disease Prophylaxis on Long-Term Outcomes in Patients Surviving Beyond Two Years After Allogeneic Transplantation.

Frailty as a Prognostic Factor in Younger Adult Patients With Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.

Herpes Zoster Frequency and Adjuvanted Recombinant Zoster Vaccination after Allogeneic Hematopoietic Cell Transplantation.

CMV reactivation post allogeneic stem cell transplantation decreases relapse risk and survival, and increases NRM - a single center analysis.

Size Does Not Always Matter: Limited Impact of Donor-recipient Weight Difference on Outcomes of Adult Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplantation.

Prior Malignancy History and Risk of Second Malignancies After Allogeneic Hematopoietic Cell Transplantation.

Ferritin as a Pre-Transplant Biomarker for Post-Transplant Outcomes in Allogeneic Stem Cell Transplantation Using Post-Transplant Cyclophosphamide.

Changes in unrelated donor usage for allogeneic hematopoietic cell transplant in Canada: 2013–2023 and identifying priorities in donor selection

Regulatory Ambiguity in Hematopoietic Cell Transplantation in India: A National Survey.

Frequent collaborators

Jonas Mattsson

Rajat Kumar

Wilson Lam

Ivan Pasic

Igor Novitzky-Basso

Tommy Moya

Eshrak Al-Shaibani

Tommy Alfaro Moya

Vikas Gupta

Santhosh Thyagu

Dennis Kim

Dawn Maze

Hassan Sibai

John Kuruvilla

Shabbir Alibhai

Wei Xu

Mohamed Elemary

Louis-Martin Rousseau

Aniket Bankar

Mark Minden

Steven Chan

Deepali Kumar

Dionne Aleman

Andre Schuh

Fotios Michelis

Rouslan Kotchetkov

Christopher Patriquin

Christine Cserti-Gazdewich

Lani Lieberman

Tracy Stockley

Christopher Lemieux

David Barth

Lina Ho

Karen Yee